Safety Evaluation of Tianzhi Granules in Treating Mild-to-moderate Vascular Dementia
10.13422/j.cnki.syfjx.20232421
- VernacularTitle:天智颗粒治疗轻中度血管性痴呆的安全性评价
- Author:
Wenfang LIU
1
;
Yang LIN
1
;
Xianfeng LIU
2
;
Fan BAI
2
Author Information
1. Beijing Anzhen Hospital of Capital Medical University， Beijing 100029， China
2. Zhongjing Wanxi Pharmaceutical Co. Ltd.， Nanyang 474500， China
- Publication Type:Journal Article
- Keywords:
Tianzhi granules;
vascular dementia;
safety;
adverse events;
adverse reactions
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(2):142-147
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo systematically evaluate the safety of Tianzhi granules used in the treatment of mild-to-moderate vascular dementia. MethodA randomized， double-blind， double-simulated， positive drug/placebo parallel controlled multi-center phase Ⅳ clinical trial and an open multi-center phase Ⅳ clinical trial of Tianzhi granules in the treatment of mild-to-moderate vascular dementia were conducted. Safety data of 1 492 patients were included and analyzed according to inclusion and exclusion criteria. The main evaluation measures were the incidence rate of adverse events/adverse reactions， laboratory indicators， vital signs， and electrocardiogram （ECG） results. ResultA total of six adverse events possibly related to the test drug occurred in 520 patients of the double-blind trial， and the symptoms were all mild and recovered. The incidence of adverse events was not statistically different among Tianzhi granules， donepezil， and placebo groups. Nine adverse events possibly related to the test drug were observed in 972 patients of the open trial， and the symptoms were mild and recovered. Laboratory tests （blood routine， urine routine， liver function， kidney function， and coagulation） and vital signs were compared before treatment （baseline） and after treatment of 12 and 24 weeks， respectively. There was no statistical significance in the main indicators before and after treatment. In the double-blinded trial， there was no significant difference in safety indicators between different groups before and after treatment. The most frequent adverse reaction was gastrointestinal discomfort， with an incidence rate of 6.64‰. ConclusionAdverse reactions occasionally occur in patients using Tianzhi granules， and it is safe to use Tianzhi granules to treat mild-to-moderate vascular dementia clinically.
